AccessOncology has evolved from a partnership created between leading executives in the Pharmaceutical industry, who have a deep understanding of the challenges in accessing specialised, life-saving medications in Australia and New Zealand.
The AccessOncology team have over 25 years experience in launching over 30 pharmaceutical products in the Asia Pacific region.
Sandra has extensive oncology expertise in developing immunotherapies, biologics & targeted agents requiring diagnostics to early and successful in-market launch in ANZ and Asia Pacific, in both R&D & generic markets. An effective leader with proven ability to build a high performing team and deliver strong P&L performance, Sandra has achieved this in both large commercial groups & specialized business units at AstraZeneca, Sanofi Aventis, Merck Serono & Alphapharm/Mylan. Sandra has also demonstrated expertise in successfully delivering clinical, regulatory, access, medical & commercial outcomes, fostered through innovation & collaborative partnerships.
Rose has over 20 years experience in large pharmaceutical companies including Eli Lilly & Sanofi Aventis and works with a solution focused attitude to overcome key challenges & drive business results with quality outcomes. Rose has a proven track record in driving new product and clinical program development including innovative trial design, Phase I to Phase IV. She has substantial market understanding & financial analysis skills which has resulted in successful product launches in Oncology, Haematology & Neurology. Her public health experience and established relationships with key influencers in Australia & New Zealand is critical in market analysis & performance delivery.